Fingerprint
Dive into the research topics where Akshara Singareeka Raghavendra is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Weight Loss Patterns and Clinical Outcomes of GLP1 Receptor Agonists in Breast Cancer Survivors
Sukumar, J. S., Raghavendra, A. S., Pasyar, S., Bassett, R. L., Tripathy, D., Barcenas, C. H., Basen-Engquist, K. M. & Arun, B. K., Jan 2026, In: Cancer Research Communications. 6, 3, p. 447-455 9 p.Research output: Contribution to journal › Article › peer-review
Open Access -
Adjuvant capecitabine in patients with triple-negative breast cancer after neoadjuvant chemotherapy
Strahan, A., Jin, Q., Raghavendra, A. S., Zakon, D. B., Grimm, M., Hughes, M. E., Cherian, M., Vincuilla, J., Parker, T., Tarantino, P., Johnson, K. C. C., Mittendorf, E. A., King, T. A., Valero, V., Tripathy, D., Tolaney, S. M., Tayob, N., Lin, N. U., Stover, D. G. & Barcenas, C. H. & 1 others, , Sep 2025, In: ESMO Open. 10, 9, 105568.Research output: Contribution to journal › Article › peer-review
Open Access -
Clinical Characteristics and Survival Outcomes of Metastatic Invasive Lobular and Ductal Carcinoma
Raghavendra, A. S., Bassett, R., Damodaran, S., Barcenas, C. H., Mouabbi, J. A., Layman, R. & Tripathy, D., Apr 2025, In: JAMA Network Open. 8, 4, 251888.Research output: Contribution to journal › Article › peer-review
Open Access2 Link opens in a new tab Scopus citations -
IL-6 predicts CDK4/6 inhibitor resistance, identifying STAT3 as a target in HR + /HER2-negative metastatic breast cancer
Kettner, N. M., Bui, T. N., Navarro-Yepes, J., Ghotbaldini, S., Quintela, B., Luo, C. K., Lam, N., Rao, X., Raghavendra, A. S., Wang, Y., Azizian, N., Kris Eckols, T., Kasembeli, M. M., Evans, K., Yi, M., Wingate, H., Wang, J., Sahin, A. A., Meric-Bernstam, F. & Hunt, K. K. & 4 others, , Dec 2025, In: npj Precision Oncology. 9, 1, 260.Research output: Contribution to journal › Article › peer-review
Open Access8 Link opens in a new tab Scopus citations -
Phase I trial of hydroxychloroquine to enhance palbociclib and letrozole efficacy in ER+/HER2− breast cancer
Raghavendra, A. S., Kettner, N. M., Kwiatkowski, D., Damodaran, S., Wang, Y., Ramirez, D., Gombos, D. S., Hunt, K. K., Shen, Y., Keyomarsi, K. & Tripathy, D., Dec 2025, In: npj Breast Cancer. 11, 1, 7.Research output: Contribution to journal › Article › peer-review
Open Access12 Link opens in a new tab Scopus citations